Assessment of the exposure-dependent perpetrator characteristics of metamizole on metabolic pathways and the pharmacokinetics of imatinib in healthy volunteers

2024-513463-96-01 Protocol K831 Human pharmacology (Phase I) - Other Ended

Start 11 Sep 2024 · End 3 Mar 2026 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol K831

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 36
Countries 1
Sites 1

Pharmacokinetic trial in healthy volunteers

Key facts

Sponsor
Universitaetsklinikum Heidelberg AöR
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Phenomena and Processes [G] - Metabolism [G03], Phenomena and Processes [G] - Biological Phenomena [G16]
Trial duration
11 Sep 2024 → 3 Mar 2026
Decision date (initial)
2024-09-02
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Pharmacokinetic trial in healthy volunteers

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Universitaetsklinikum Heidelberg AöR

Sponsor organisation
Universitaetsklinikum Heidelberg AöR
Address
Im Neuenheimer Feld 672, Neuenheim Neuenheim
City
Heidelberg
Postcode
69120
Country
Germany

Scientific contact point

Organisation
Universitaetsklinikum Heidelberg AöR
Contact name
Clinical Trial Unit (Internal Medicine IX, Department Clinical Pharmacology & Pharmacoepidemiology)

Public contact point

Organisation
Universitaetsklinikum Heidelberg AöR
Contact name
Clinical Trial Unit (Internal Medicine IX, Department Clinical Pharmacology & Pharmacoepidemiology)

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 36 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
Universitaetsklinikum Heidelberg AöR
Internal Medicine IX: Department of Clinical Pharmacology and Pharmacoepidemiology, Im Neuenheimer Feld 410, Neuenheim, Heidelberg

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-09-11 2024-10-01 2026-03-03

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-22 Germany Acceptable
2024-08-28
2024-09-02
2 SUBSTANTIAL MODIFICATION SM-1 2024-11-29 Germany Acceptable
2024-12-23
2024-12-27
3 SUBSTANTIAL MODIFICATION SM-2 2025-04-22 Germany Acceptable
2025-05-14
2025-05-19